Buprenorphine and Integrated HIV Care Evaluation

• Status: Unknown status
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The New York Academy of Medicine
• Collaborators: Brown University; CORE Center, Cook County Bureau of Health Services; El Rio Santa Cruz Neighborhood Health Center; Health Resources and Services Administration (HRSA); Johns Hopkins University; Montefiore Medical Center; Oregon Health and Science University; Organization to Achieve Solutions in Substance Abuse (OASIS); University of California, San Francisco; University of Miami; Yale University
• Treatments: Analgesics, Opioid; Buprenorphine

Criteria

Inclusion Criteria:

• HIV-infected

• Clinical diagnosis of opioid dependence

• Fluent in English or Spanish

• 18 years or older

Exclusion Criteria:

• Liver function tests (transaminase only) at five times or higher than normal level;

• Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for benzodiazepine abuse or dependence within the past 6 months;

• DSM-IV criteria for alcohol dependence within the past 6 months;

• Actively suicidal;

• Psychiatric impairment that impedes ability to consent (dementia, delusional, actively psychotic);

• Methadone dose exceeding levels allowing for safe transition to buprenorphine;

• Pregnant women and women actively trying to become pregnant;

• Clinical judgment of local site principal investigator that patient is inappropriate